{"nctId":"NCT00909532","briefTitle":"Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation","startDateStruct":{"date":"2009-06"},"conditions":["Cystic Fibrosis"],"count":167,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"150 mg Ivacaftor q12h","type":"EXPERIMENTAL","interventionNames":["Drug: Ivacaftor"]}],"interventions":[{"name":"Ivacaftor","otherNames":["VX-770"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed diagnosis of cystic fibrosis (CF) and G551D mutation in at least 1 allele\n* Forced expiratory volume in 1 second (FEV1) of 40% to 90% (inclusive) of predicted normal for age, gender, and height at Screening.\n* No clinically significant abnormalities that would have interfered with the study assessments, as judged by the investigator\n* Willing to use highly effective birth control methods during the study\n\nExclusion Criteria:\n\n* History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject\n* Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1 of the study\n* History of alcohol, medication or illicit drug abuse within one year prior to Day 1\n* Abnormal liver function â‰¥ 3x the upper limit of normal\n* Abnormal renal function at Screening\n* History of solid organ or hematological transplantation\n* Pregnant, planning a pregnancy, breast-feeding, or unwilling to follow contraception requirements\n* Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days prior to Screening\n* Use of inhaled hypertonic saline treatment\n* Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP 3A4)","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24","description":"Spirometry (as measured by FEV1) is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.7"},{"groupId":"OG001","value":"10.4","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Absolute Mean Change From Baseline in Percent Predicted FEV1 Through Week 48","description":"Spirometry (as measured by FEV1) is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.7"},{"groupId":"OG001","value":"10.1","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Score Through Week 24 and Week 48 (Respiratory Domain Score, Pooled)","description":"The CFQ-R is a health-related quality of life measure for subjects with cystic fibrosis. Each domain is scored from 0 (worst) to 100 (best). A difference of at least 4 points in the respiratory domain score of the CFQ-R is considered a minimal clinically important difference (MCID).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.3"},{"groupId":"OG001","value":"6.0","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"1.2"},{"groupId":"OG001","value":"6.0","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Sweat Chloride Concentration Through Week 24 and Week 48","description":"The sweat chloride (quantitative pilocarpine iontophoresis) test is a standard diagnostic tool for cystic fibrosis (CF), serving as an indicator of cystic fibrosis transmembrane conductance regulator (CFTR) activity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.3"},{"groupId":"OG001","value":"-48.7","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.3"},{"groupId":"OG001","value":"-48.7","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Time-to-first Pulmonary Exacerbation Through Week 24 and Week 48","description":"Pulmonary exacerbation was defined as a change in antibiotic therapy (intravenous, inhaled, or oral) for any 4 or more of signs/symptoms such as change in sputum; new or increased hemoptysis; increased cough or dyspnea; malaise, fatigue, or lethargy; temperature above 38 degrees C; anorexia or weight loss; sinus pain/tenderness and discharge; change in physical examination of the chest; decreased pulmonary function by 10%; and radiographic changes indicative of pulmonary infection.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":null},{"groupId":"OG001","value":"0.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.87","spread":null},{"groupId":"OG001","value":"0.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":null},{"groupId":"OG001","value":"0.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":null},{"groupId":"OG001","value":"0.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":null},{"groupId":"OG001","value":"0.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":null},{"groupId":"OG001","value":"0.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":null},{"groupId":"OG001","value":"0.67","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Weight at Week 24 and Week 48","description":"As malnutrition is common in patients with cystic fibrosis (CF) because of increased energy expenditures due to lung disease and fat malabsorption, body weight is an important clinical measure of nutritional status.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.4"},{"groupId":"OG001","value":"3.0","spread":"0.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.5"},{"groupId":"OG001","value":"3.1","spread":"0.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":78},"commonTop":["Cystic fibrosis lung","Cough","Oropharyngeal pain","Headache","Upper respiratory tract infection"]}}}